The regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor and ruzasvir, an NS5A inhibitor, is advancing in a global Phase 3 development program for the treatment of hepatitis C virus (HCV). In a global Phase 2 study, the regimen met its primary endpoints of efficacy and safety. As single agents, both bemnifosbuvir and ruzasvir have demonstrated potent pan-genotypic antiviral activity against HCV.
Atea is a clinical stage biopharmaceutical company working to address unmet medical needs with innovative oral antiviral therapies.
Hepatitis C (HCV)
Hepatitis C (HCV)
Leveraging our deep understanding of antiviral drug development, medicinal chemistry, biology, biochemistry and virology, we are discovering and developing novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Currently, we are focused on the development of orally-available direct-acting antiviral agents for the treatment of hepatitis C virus (HCV).
Updates on the regimen of bemnifosbuvir and ruzasvir for the treatment of HCV and
other Atea news.
Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted Outside North America, Enrollment Completion Expected Mid-2026 with Topline Results Anticipated Year-End 2026
BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD,
Patient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North America Trial Expected Mid-2026 New Data Show Bemnifosbuvir Has Unique Dual Mechanism Against HCV New Data Presented at The Liver Meeting ® , the Annual Meeting of AASLD,
Atea is a clinical-stage biopharmaceutical company committed to addressing unmet medical needs through novel antiviral treatments.
Copyright © 2025 By Atea Pharmaceuticals. All Rights Reserved. Privacy Policy | Terms of Use